Novice Karate Group (ages 8 & up)

Nucleic acid testing has become the gold standard in the Blood Screening Market for its ability to detect infections during the early “window period” before antibodies are produced. NAT can identify pathogens such as HIV, HBV, and HCV with high sensitivity, significantly reducing transfusion-transmitted infection risks. MRFR forecasts the market’s value to climb from USD 3.40 billion in 2024 to USD 5.60 billion by 2032. Many countries are mandating NAT for all donated blood, pushing demand for these platforms even in regions with limited budgets. Vendors that can deliver cost-effective NAT solutions are expected to see strong uptake, especially in emerging economies aiming to align with WHO safety guidelines.